Associated Papers
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
36430388 (PubMed )
Supplement: ijms-23-13898-s001.zip › ijms-1981646-supplementary.pdf
Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.
Shang Y et al.
Frontiers in Oncology, 2022
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R et al.
Cancer Research, 2011
Select a paper to view details